A new treatment to prevent severe immune reactions in CAR T-cell therapy patients
Official title: CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients
Funded at Cytoagents, INC. · NIH-10920629 · Data updated 2026-11-12
This study is testing a new medication called CTO1681 to see if it can help prevent and treat serious side effects from CAR T-cell therapy for blood cancers, making the treatment safer and more effective for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cytoagents, INC. NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $994,859 |
| NIH project number | 1R44CA287634-01A1 |
| Project ID | NIH-10920629 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing CAR T-cell therapy for relapsed or refractory hematologic malignancies.
✕Less likely to help
Patients who are not receiving CAR T-cell therapy or those with other unrelated health conditions may not benefit from this research.
What this research studies
This research focuses on developing a medication called CTO1681 to prevent and treat cytokine release syndrome (CRS), a serious side effect of CAR T-cell therapy used for certain blood cancers. CAR T-cell therapy can be very effective but often leads to severe immune reactions that can be life-threatening. The study aims to reduce the levels of inflammatory substances in the body that contribute to these reactions, potentially improving patient safety and outcomes. Patients will receive CTO1681 to see if it can help mitigate these adverse effects during their CAR T-cell treatment.
Why it matters
Potential benefit: If successful, this research could significantly enhance the safety of CAR T-cell therapy for patients by reducing the risk of severe immune reactions.
How similar studies have gone: Other research has shown promise in using similar approaches to manage cytokine release syndrome, indicating potential for success in this area.
Where this research is happening
-
Cytoagents, INC.
Pittsburgh, United States Active
Researchers
- Principal investigator: Bertolino, Arthur P — Cytoagents, INC.
- Study coordinator: Bertolino, Arthur P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.